Vitae Pharmaceuticals Priced, Nasdaq: VTAE
Developing small molecule drugs for type 2 diabetes and Alzheimer's.
Industry: Health Care
First Day Return: -4.9%
VTAE
Developing small molecule drugs for type 2 diabetes and Alzheimer's.
| IPO Data | |
|---|---|
| IPO Date | 09/24/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $55 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Fort Washington, PA, United States |
| Founded | 2001 |
| Employees at IPO | 52 |
| Website www.vitaepharma.com | |
IPO News for Vitae Pharmaceuticals
Vitae Pharmaceuticals (VTAE) Performance
